Company intelligence / Profile preview

JDS Pharmaceuticals

New York, New York, United Statesjdspharma.com ↗

Ownership: Private
Development stage: Other

Overview

JDS successfully marketed two branded prescription psychiatry products—Lithobid® and Pexeva®. Lithobid® was the only branded sustained-release lithium carbonate product in the U.S., indicated for maintenance of bipolar disorder. Pexeva® is a branded paroxetine mesylate product indicated for several psychiatric disorders. The company advanced a once-daily lithium formulation ("Lithium QD") to Phase 3 trials and developed Mesafem™, a low-dose paroxetine capsule targeting menopausal vasomotor symptoms that was expected to enter Phase 3 at time of acquisition by Noven.

Therapeutic areas: Women's HealthPsychiatry
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

No major external pharma partnerships disclosed pre-acquisition. Post-acquisition activities integrated into Noven's network.

Beyond the preview

Go deeper on JDS Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JDS Pharmaceuticals.